Prognosis

Retrospective data indicate that de novo MBC, premenopausal status, oestrogen receptor (OR)-positive status, HER2-positive disease, and fewer metastatic sites are significantly associated with long-term MBC survival (defined as ≥5 years) among women diagnosed with MBC.[179][180]

One patient cohort reported improved overall survival over the study period (2010 to 2018), with a considerable proportion of patients alive at 8 years.​[180] An earlier study, employing back-calculation methods, estimated an increase in 5-year relative survival rate among women diagnosed with de novo MBC (at age 15-49 years) from 18% between 1992-1994 to 36% between 2005-2012.[181]​ Improved survival in these studies coincides with significant therapeutic advances for HER2-positive MBC.

The median overall survival of patients with MBC is 2-3 years.[182][183][184]​​​

In the UK, 5-year survival of women diagnosed with stage 4 breast cancer (2013-2017, followed up to 2018) is estimated to be 26%.[185] ​In the US, 5-year relative survival rate for women with de novo MBC is 31% (data from 2013 to 2019).[19]

Use of this content is subject to our disclaimer